SONIC HEALTHCARE LIMITED Overview
Sonic Healthcare is the world's third-largest provider of pathology and clinical laboratory services and the first to operate on a genuinely global basis, generating A$10.87 billion of FY2026 revenue across nine countries and 11 markets. It is the largest private laboratory operator in Australia, Germany, Switzerland, the UK and Liechtenstein, second in Belgium and New Zealand, third in the United States, and has a presence in Poland. Domestically, it is also Australia's second-largest diagnostic imaging provider and the largest operator of medical centres, skin cancer clinics and occupational health services. Its differentiation rests on a "Medical Leadership" culture and a federated structure that preserves local brands and pathologist autonomy, which makes Sonic the preferred acquirer for founder-led laboratories. The investment proposition, as restated by new CEO Dr Jim Newcombe, is "high-value medicine at scale": scale and diversification, Medical Leadership, and operational excellence, now augmented by digital/AI transformation and sharper capital discipline.
Company's own description (AR2026, paraphrased)
Sonic describes itself as one of the world's leading providers of medical diagnostic services, contributing to the care of more than 140 million patients in FY2026. It provides highly specialised pathology/clinical laboratory and diagnostic imaging services to general practitioners, specialists, hospitals and community health services and their patients. Its principal activities are the provision of medical diagnostic services and of administrative services and facilities to medical practitioners. Laboratories offer a menu of more than 3,000 tests, with large hubs operating at or above tertiary teaching hospital standards. Sonic states that laboratory tests influence roughly 70% of healthcare decisions and 100% of cancer diagnoses.
Business model
Sonic operates a hub-and-spoke diagnostic network. Specimens are collected at company-operated collection centres (in Australia, UK, US) or by referring doctors (approximately 35% of Australian specimens; in Germany, Belgium and Switzerland laboratories generally do not collect), couriered to regional hub laboratories, processed on automated platforms or by specialist pathologists, and reported electronically to the referring doctor. Imaging follows a clinic-based model with radiologist reporting. Primary care (Sonic Clinical Services) provides facilities and administrative services to ~2,000 independent GPs in more than 200 clinics.
The model's economic engine is operating leverage: high fixed costs (laboratory infrastructure, logistics, IT, pathologist workforce) amortised over rising test volumes. Market leadership in each geography produces density economics in logistics and procurement, and acquired laboratories are progressively merged into hubs to extract synergies.
Revenue model
| Revenue type | Description | Mix (independent characterisation) |
|---|---|---|
| Fee-for-service (public payer) | Government fee schedules: Medicare Benefits Schedule (Australia), EBM statutory insurance schedule (Germany), Swiss Analysenliste, Belgian INAMI/RIZIV, US Medicare CLFS/PFS | Majority of group revenue (exact split not publicly disclosed) |
| Fee-for-service (private payer / patient) | Private insurance (GOÄ in Germany; commercial insurers in US), private billing and gap fees (Australia), direct-to-consumer testing (e.g., Mein Direktlabor, Germany) | Material and growing (DTC grew >60% in Germany in FY2026) |
| Long-term outsourcing contracts | NHS pathology partnerships (e.g., 15-year Hertfordshire & West Essex contract, started 1 March 2025); hospital laboratory contracts (e.g., North Shore Private, Hollywood Private) | Growing; not separately disclosed |
| Facilities/administrative services | Service fees from GPs in IPN medical centres, skin clinics, occupational health contracts | ~4.6% of revenue (Other segment, FY2026) |
| Product/trading | Medical consumables trading and logistics acquired with LADR (Germany) | Small; not separately disclosed |
| Subscription/licensing | Not material; PathologyWatch digital pathology is used internally | Not material |
Sonic is overwhelmingly a service business; product, subscription and licensing revenue is immaterial.
Value chain position
Sonic sits in the provider layer of the diagnostics value chain: downstream of in-vitro diagnostic (IVD) instrument and reagent manufacturers (Roche, Abbott, Siemens Healthineers, Beckman Coulter, Sysmex), and upstream of clinical decision-making by referring doctors. It captures value through test interpretation (pathologist medical reporting), scale-driven unit cost, and the referral relationship. Its bargaining power vis-à-vis suppliers is high (it completed a major national laboratory platform procurement in Australia in FY2026), but its pricing power vis-à-vis payers is weak because most fees are set administratively.
Customer types and end-markets
Referring customers: GPs, medical specialists (oncologists, dermatologists, gastroenterologists, haematologists), hospitals (public and private), national screening programmes (e.g., Australian National Bowel Cancer Screening contract renewal, FY2025), occupational/employer clients, insurers and, increasingly, consumers directly. Payers: governments, statutory and private insurers, patients. End-markets: clinical laboratory testing (routine and esoteric), anatomical pathology/histopathology (cancer diagnosis), genetics and molecular testing, diagnostic imaging (MRI, CT, PET-CT, ultrasound, X-ray, mammography, nuclear medicine), primary care and occupational health.
Independent characterisation
Sonic is best understood as a multi-country roll-up of regulated, utility-like healthcare service franchises, held together by a distinctive cultural model rather than by a centralised operating system. Its strengths — local brand equity, doctor loyalty, low senior-staff turnover — are precisely those of a federation; its weaknesses — historically fragmented IT, slower synergy capture, and uneven performance across geographies (notably the US) — are also federation artefacts. The new CEO's agenda (consolidating 11 German federation members into three divisions; cloud-based back office; US operating review) represents a measured shift from pure federation toward a more integrated "federation-plus" model.
Strategy
Stated strategy (AR2026 themes, paraphrased)
Investment proposition: "high-value medicine at scale", underpinned by three differentiators — scale and diversification, Medical Leadership culture, operational excellence.
Growth model: organic growth (incl. outsourcing contract wins) plus value-enhancing acquisitions/JVs to build leading positions in targeted laboratory markets, then synergy capture and scale economies.
Market selection: politically, legally and financially stable countries with reliable healthcare funding, fragmented markets and cultural fit.
Organic growth expectation: long-run market organic growth ~5% p.a., with potential to be higher.
Technology: AI expected to drive step-changes in pathology and radiology efficiency, quality and capacity; investment in digital pathology.
Capital management priorities: investment-grade balance sheet; progressive dividends with 70–80% medium-term payout target; selective synergistic acquisitions; buybacks when surplus capital and conditions allow; improve EPS and ROIC.
Strategic initiatives — last 24 months
| Initiative | Launched | Description | Targets / status |
|---|---|---|---|
| LADR acquisition & integration | Jul 2025 | Germany's oldest lab practice; EV €423m; ~€370m revenue, ~€50m EBITDA (CY2024) | >40% of synergies realised year one; return above cost of capital; A$59m NPAT FY2026 |
| German operational realignment | Jul 2026 | 11 federation members → 3 unified operating divisions | Accelerate consolidation and synergies |
| Bremen national reference laboratory | Apr 2026 (planned go-live) | Centralised esoteric testing | — |
| Swiss laboratory consolidation | FY2025–FY2027 | Integration of SYNLAB Suisse and Dr Risch; mergers in Geneva, Lausanne, Zurich, Ticino done; Berne, Lucerne FY2027 | Synergies peaking FY2026–FY2027 |
| US operating review | FY2026 | Practice rationalisation, procurement, headcount reduction, reference testing optimisation, centralisation of compliance/legal/HR/marketing | A$25–30m added to FY2027 earnings (locked in); further options under review |
| US Advanced Diagnostics division | FY2026 | Cairo Diagnostics national expansion, ThyroSeq | +16% organic FY2026 |
| US revenue collection system | FY2025–FY2027 | Billing upgrade | US$20–25m revenue uplift now expected FY2027 |
| HWE NHS contract | Mar 2025 | 15-year integrated pathology network; Watford hub | Planned margins by 2H FY2028 (delayed) |
| Australian lab platform procurement | FY2026 | National instrument/reagent tender | "Significant savings" |
| Docklands hub (Melbourne) | Opening mid-2027 | New hub laboratory | Potential sale-and-leaseback |
| Global digital transformation | FY2026 | Cloud back office (finance, supply chain, HR), lab/radiology workflow, AI clinical apps | ~A$30m p.a. for three years (back office); excluded from guidance |
| Property capital recycling | FY2026 | Brisbane sale-and-leaseback A$445m (5.6% yield); 95 Epping Rd conditional sale; Docklands and Macquarie Park SLB under evaluation | Completed/ongoing |
| Radiology greenfield programme | FY2025–FY2026 | Ten new sites | Accretive ~18 months post-opening |
| SCS restructuring | FY2026 | Shared services across medical centres, occupational health, skin | Further benefits FY2027 |
| Global Leaders Summit | FY2026 | Alignment on strategic priorities to 2030 | Ongoing |
| ESG | Ongoing | First AASB S2 climate disclosures; scope 3 assurance preparation | Achieved FY2026 milestones |
Guidance and medium-term targets
| Item | Guidance | Basis |
|---|---|---|
| FY2027 EBITDA | A$1.95–2.03 billion | Constant currency (FY2026 rates); excludes ~A$30m IT transformation costs and property sale gains; assumes no further regulatory changes and only completed acquisitions |
| FY2026 EBITDA (for reference) | A$1.87–1.95bn CC — achieved at A$1.916bn underlying CC | Issued Aug 2025, reaffirmed Nov 2025 and Feb 2026 |
| Dividend payout | 70–80% of net profit (medium term) | Capital management policy |
| Maintenance capex | ~3–3.5% of revenue longer term | H1 FY2026 call |
| Leverage | Investment-grade balance sheet; covenants debt cover <3.5x | AR2026 |
Midpoint FY2027 guidance (A$1.99bn) implies ~3% growth on FY2026 underlying EBITDA (A$1.933bn), reflecting Swiss fee cuts, HWE delays and IT costs being excluded.
Products & Services
Sonic does not publish list prices; pricing is predominantly set by payer fee schedules. Launch years are given where disclosed.
Laboratory medicine (all laboratory segments)
| Service line | Description / capabilities | Target customer | Pricing model | Flagship / named offerings |
|---|---|---|---|---|
| Biochemistry | Measurement of chemical substances in blood/fluids; high-throughput automated chemistry | GPs, specialists, hospitals | Fee schedule (MBS, EBM, CLFS) | Core routine panels |
| Haematology | Blood cell analysis, coagulation, haematological malignancy work-up | GPs, haematologists | Fee schedule | Cairo Diagnostics haem-onc integrated reports (US) |
| Microbiology | Bacterial, fungal, parasitic and viral detection, susceptibility testing | GPs, hospitals, infection control | Fee schedule | Molecular infectious disease panels |
| Immunoserology | Antibody measurement, immune status, autoimmune serology | GPs, specialists | Fee schedule | — |
| Histopathology | Tissue diagnosis by anatomical pathologists, chiefly cancer | Surgeons, dermatologists, oncologists | Fee schedule / PFS (US) | Aurora Diagnostics practices; ProPath; Cellular Pathology Services (UK, acquired FY2026) |
| Cytopathology | Cell-level cancer/pre-cancer detection | GPs, gynaecologists, screening programmes | Fee schedule / programme contracts | Cervical screening |
| Dermatopathology (digital) | >70% of US dermatopathology volume processed via proprietary digital platform | Dermatologists | PFS / commercial | PathologyWatch (acquired FY2024) |
| Genetics | DNA/RNA/chromosome testing for inherited disorders and cancer | Specialists, oncologists, prenatal care | Mix of schedule and private billing | Sonic Genetics (Australia, +15% growth FY2026) |
| Molecular pathology | Diagnostic and prognostic DNA/RNA/protein testing | Oncologists | Schedule / commercial | ThyroSeq® molecular thyroid classifier (US); liquid biopsy development (Cairo) |
| Prenatal testing | Preconception and first/second trimester screening, NIPT | Obstetricians, patients | Private billing | NIPT offerings |
| Toxicology | Drugs, chemicals, toxins | Employers, clinicians | Contract / schedule | Workplace drug testing via Sonic HealthPlus |
| Specialised biochemistry / functional diagnostics | Micronutrient, gut microbiome and specialised testing | Specialists, consumers | Private | Biovis (Germany, +12% growth FY2026) |
| Direct-to-consumer testing | Consumer-initiated testing ordered online | Consumers | Private pay | Mein Direktlabor (Germany, >60% growth FY2026) |
| Hospital laboratory outsourcing / management | Full or partial operation of hospital labs; NHS pathology partnerships | Hospitals, NHS trusts | Long-term contracts | HWE NHS contract (15 years, from Mar 2025; Watford hub lab); North Shore Private and Hollywood Private (Perth, from Feb 2026) hospital contracts |
| National screening | Population screening programmes | Governments | Tendered contracts | Australian National Bowel Cancer Screening Program (renewed FY2025) |
| Medical consumables trading & logistics | Supply of consumables to referring doctors | German referring doctors | Product sale | LADR trading business (acquired Jul 2025) |
| Reference laboratory services | National esoteric testing hub | Group labs, external labs | Inter-lab / schedule | Bremen national reference laboratory (Germany; go-live planned April 2026) |
Radiology – Australia
| Modality | Description | Notes |
|---|---|---|
| MRI | High-value cross-sectional imaging | Growth affected by DVA referral guideline change (annualised by FY2026 end) |
| CT | Cross-sectional imaging | Growing high-value modality |
| PET-CT / nuclear medicine | Oncology staging, functional imaging | Growing high-value modality |
| Ultrasound, X-ray, mammography, bone densitometry | Routine imaging | — |
| Interventional radiology | Image-guided procedures | — |
| AI-enabled reporting tools | Radiologist productivity and workflow tools | Deployment continuing (AR2026) |
| Network expansion | Ten greenfield sites opened over FY2025–FY2026; accretive ~18 months after opening on average | AR2026 |
Sonic Clinical Services (Other segment)
| Business | Description | Scale |
|---|---|---|
| IPN Medical Centres | Facilities and administrative services to independent GPs | Part of >200 clinics, ~2,000 GPs |
| Sonic HealthPlus | Australia's largest occupational health provider (pre-employment medicals, injury management, drug testing) | National |
| Skin health | Australian Skin Cancer Clinics and National Skin Cancer Clinics (acquired Apr 2025) — largest skin cancer clinic operator in Australia | National |
Digital and technology platforms (internal)
| Platform / programme | Description | Status |
|---|---|---|
| PathologyWatch | Proprietary digital pathology platform | >70% of US dermpath volume (FY2026) |
| Global digital transformation | Cloud migration of finance, supply chain and HR; laboratory/radiology operating system optimisation; AI-enabled patient, doctor and clinical applications | Launched FY2026; ~A$30m p.a. for three years for back office (excluded from FY2027 guidance) |
| US enhanced revenue collection system | Billing/collections upgrade; US$20–25m revenue uplift deferred from FY2026 to FY2027 | H1 FY2026 call (TipRanks) |
Financial Narrative
All figures A$ M unless stated; source AR2026 Financial History and Directors' Report unless noted. FY2022 and FY2023 contain large COVID-19 testing profits.
Income statement
Notes: FY2024 underlying EBITDA and net profit exclude the A$32m (pre-tax/after-tax ~A$32m) gain on sale of the US West division; other FY2024 non-recurring items, if any, not adjusted. FY2022–FY2025 pre-tax income from stockanalysis.com (FY2025 figure reconciles exactly to the company's A$750.9m); FY2026 pre-tax income computed from AR2026 (EBITA A$1,110.4m − amortisation A$97.5m − net interest A$188.3m = A$824.5m).
Supplementary income detail
Source: stockanalysis.com (Sonic does not report gross profit; this is an aggregator construct). FY2026 not available on a consistent basis.
FY2025/FY2026 COVID revenue no longer separately disclosed (immaterial); shown as zero for charting.
Reported effective tax rate FY2026 22.8%; underlying ~26% (guidance had been ~27%).
Margins
Revenue CAGR FY2022–FY2026: 3.9% (total); ~12.0% (base business ex-COVID). EBITDA (constant currency) five-year CAGR vs FY2021 base: (7.2)% (AR2026 remuneration table).
Balance sheet
FY2026 drawn debt structure (AR2026): USPP notes US$550m and €685m (fixed coupons); bank facilities drawn €599m and CHF448m; AUD A$607m and USD US$100m bank lines undrawn; available liquidity A$1,633m.
Net assets movement FY2026: +A$371m shares issued for LADR; +A$84m retained earnings; +A$30m share-based payments; −A$396m FX translation; −A$65m minority interest transactions.
Cash flow
Sources: AR2026 (OCF); stockanalysis.com (capex, FCF). FY2026 capex of A$631m included property spending; maintenance capex was A$351m (~3% of revenue) per the FY2026 earnings call. Gross operating cash flow equalled 93% of EBITDA (ex non-cash NRIs) in FY2026, depressed by Change Healthcare advance repayments (~US$18m still to repay after 30 June 2026) and 26% higher interest payments. Payments for acquisitions and investments: A$625m in FY2026. Dividends declared for FY2026 totalled A$533.8m (interim A$222.4m paid 19 March 2026; final A$311.4m paid 17 September 2026); FY2025 A$522.7m. Dividend Reinvestment Plan suspended throughout FY2025–FY2026. Share buybacks: none in FY2025 or FY2026; buybacks remain a stated capital-management option "where surplus capital and market conditions support them".
Ratios
ROE/ROIC/covenant ratios per AR2026 (covenant definitions exclude AASB 16); ROA, net debt/equity and asset turnover computed. Current ratio and cash conversion cycle: not publicly disclosed in extracted materials. Covenant limits: debt cover <3.5x, interest cover >3.25x, gearing <55%.
Trend commentary
Revenue. The five-year record is dominated by the COVID-19 boom and bust: COVID testing contributed A$2.43bn in FY2022, A$485m in FY2023 and A$62m in FY2024, and is now negligible. Stripping it out, base business revenue compounded at roughly 12% from FY2022 to FY2026, driven by ~5% organic growth plus acquisitions (SYNLAB Suisse, Dr Risch, PathologyWatch, National Skin Cancer Clinics, LADR, Cairo) and the HWE NHS contract. FY2026's 12.7% statutory growth was the strongest post-pandemic print, with Europe now 46.5% of revenue.
Margins. The underlying EBITDA margin has compressed from ~30% at the COVID peak to a structurally lower 17.8–18.1% band. FY2024 marked the trough (inflationary labour costs, COVID unwind). FY2025 showed 40bps normalised expansion; FY2026 showed mix-driven dilution (LADR's trading business, HWE ramp, US weakness) despite labour cost falling 30bps as a percentage of revenue. Margin recovery depends on US restructuring, HWE reaching planned margins (now 2H FY2028) and Swiss/German synergies.
Below EBITDA. Depreciation (A$771m in FY2026, including AASB 16 right-of-use depreciation) consumes ~40% of EBITDA, making Sonic's EBIT margin only ~9%. Net interest rose 18.6% in FY2026 on acquisition debt. The FY2026 tax line was flattered by the sale-and-leaseback structure (use of ~A$170m of unrecognised capital losses).
Returns. ROIC has sat at 5.9–6.5% for three years, below the 9% LTI targets set for FY2024–FY2025, and the FY2024–FY2026 LTI tranche vested at 0%. This is the single most important strategic issue: Sonic has deployed substantial capital into acquisitions at returns only around its cost of capital, while the market has de-rated the stock (three-year TSR to 30 June 2026 of −35.0%).
Balance sheet. Net debt rose from A$0.8bn (FY2022) to A$3.1bn (FY2026) as acquisitions were debt-funded, but leverage remains moderate at 2.2x, interest cover is 10x, and liquidity is A$1.6bn. The sale-and-leaseback programme is a deliberate lever to recycle property capital at ~5.6% pre-tax cost.
Dividends. Sonic has maintained or grown its dividend for more than three decades. Payout exceeded 100% in FY2025 and fell back to 87.7% in FY2026, still above the 70–80% medium-term target; franking rose to 60%.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key brands/operations |
|---|---|---|
Laboratory – Australia and New Zealand | Clinical and anatomical pathology, genetics, screening in Australia and NZ | Douglass Hanly Moir Pathology, Sullivan Nicolaides Pathology, Melbourne Pathology, Sonic Genetics, Clinipath, Capital Pathology, Barratt & Smith, others |
Laboratory – USA | Clinical laboratory, anatomical pathology, esoteric/advanced diagnostics | Sonic Healthcare USA (CPL, Aurora Diagnostics practices, ProPath, CBLPath/ThyroSeq, Cairo Diagnostics, PathologyWatch) |
Laboratory – Europe | Germany, Switzerland, UK, Belgium, Poland, Liechtenstein | Sonic Healthcare Germany (Bioscientia, LADR, Biovis, Mein Direktlabor, etc.); Sonic Suisse (Medica, SYNLAB Suisse, Dr Risch); TDL/HSL & Sonic UK; AML (Belgium); LADR Poland |
Radiology – Australia | Diagnostic imaging | Sonic Imaging network (e.g., Castlereagh Imaging, Queensland X-Ray, Canberra Imaging) |
Other | Sonic Clinical Services (SCS) — medical centres, occupational health, skin health — plus minor operations and corporate costs | IPN Medical Centres, Sonic HealthPlus, Australian Skin Cancer Clinics, National Skin Cancer Clinics |
Revenue by Segment
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Laboratory – ANZ (AUD Mn) | 1,994 | 2,104 | 2,213 |
Laboratory – USA (AUD Mn) | 2,147 | 2,110 | 2,048 |
Laboratory – Europe (AUD Mn) | 3,475 | 3,975 | 5,055 |
Radiology – Australia (AUD Mn) | 880 | 970 | 1,037 |
Other (AUD Mn, derived) | 446 | 465 | 499 |
Operating revenue total (AUD Mn) | 8,942 | 9,624 | 10,852 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Revenue
| Segment | FY2025 growth (CC) | FY2026 growth (CC) | FY2026 growth (statutory) | % of FY2026 revenue |
|---|---|---|---|---|
Laboratory – ANZ | 5.5% | 5.2% | 5.2% | 20.4% |
Laboratory – USA | (3.0)% | 1.7% | (2.9)% | 18.9% |
Laboratory – Europe | 11.4% | 24.5% | 27.2% | 46.5% |
Radiology – Australia | 10.2% | 6.9% | 6.9% | 9.6% |
Other (SCS) | — | 7.3% | 7.3% | 4.6% |
Markets
| Market | Underlying EBITDA margin direction FY2026 | Drivers |
|---|---|---|
Germany (excl. LADR), Switzerland, SCS | Strong expansion | Operating leverage, advanced diagnostics growth, synergy capture, cost discipline |
Australian Pathology, Belgium | Maintained | Fee impacts offset by organic growth, private billing, specialist referrals |
USA | Lower | Low organic growth; operating review under way |
UK | Lower | HWE integration delay, labour cost increase |
Radiology | Lower | Greenfield dilution, Department of Veterans' Affairs MRI referral change |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 9,340 | 8,169 | 8,967 | 9,645 | 10,867 |
Revenue growth YoY (%) | 6.7 | -12.5 | 9.8 | 7.6 | 12.7 |
EBITDA statutory (AUD Mn) | 2,830 | 1,708 | 1,635 | 1,725 | 1,882 |
EBITDA underlying (AUD Mn) | 2,830 | 1,708 | 1,602 | 1,747 | 1,933 |
Pre-tax income (AUD Mn) | 2,077 | 931 | 731 | 751 | 825 |
Net profit attributable statutory (AUD Mn) | 1,461 | 685 | 511 | 514 | 608 |
Net profit underlying (AUD Mn) | 1,461 | 685 | 479 | 531 | 621 |
Diluted EPS statutory (A$ cents) | 302.5 | 145.0 | 107.2 | 106.7 | 123.0 |
Dividends declared per share (A$ cents) | 100 | 104 | 106 | 107 | 108 |
Dividend payout ratio (%) | 32.5 | 71.7 | 99.4 | 101.8 | 87.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansKey Financials and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross profit, third-party basis (AUD Mn) | 3,426 | 3,726 | 2,842 | 2,945 | 3,188 |
Gross margin, third-party basis (%) | 39.1 | 39.9 | 34.8 | 32.8 | 33.1 |
Income Statement
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Base business revenue ex-COVID (AUD Mn) | 6,912 | 7,684 | 8,905 | 9,645 | 10,867 |
COVID-19 revenue (AUD Mn) | 2,429 | 485 | 62 | 0 | 0 |
Income Statement and Per-Share Data
| FY2026 vs FY2025 detail (AUD Mn) | FY2025 | FY2026 statutory | FY2026 CC | Growth (stat.) |
|---|---|---|---|---|
EBITDA before non-recurring | 1,747.1 | 1,933.1 | 1,915.9 | 10.6% |
Non-recurring items (net) | (22.1) | (51.2) | (52.7) | — |
Depreciation | (722.5) | (771.5) | (769.0) | 6.8% |
EBITA | 1,002.5 | 1,110.4 | 1,094.2 | 10.8% |
Amortisation of intangibles | (92.8) | (97.5) | (98.5) | 5.1% |
EBIT (computed) | 909.6 | 1,012.9 | 995.7 | 11.4% |
Net interest expense | (158.8) | (188.3) | (187.8) | 18.6% |
Income tax | (206.9) | (188.2) | (184.1) | (9.0)% |
Minority interests | (30.3) | (28.0) | (27.9) | (7.6)% |
Net profit attributable | 513.6 | 608.3 | 596.0 | 18.4% |
Basic EPS (cents) | 107.0 | 123.1 | 120.6 | 15.0% |
Underlying diluted EPS (cents) | 110.3 | 125.6 | 123.2 | 13.9% |
Financial Analysis
| Item (AUD Mn) | EBITDA impact | Tax effect | NPAT impact |
|---|---|---|---|
Gain on Brisbane hub sale-and-leaseback | 106.7 | 19.9 | 126.6 |
US debtors adjustment (Change Healthcare-related; revenue recognised FY2024–25) | (33.0) | 8.4 | (24.6) |
Australian wage remediation (pre-FY2026 periods) | (14.0) | 4.2 | (9.8) |
Software intangibles impairment | (82.8) | 24.8 | (58.0) |
Acquisition costs | (8.2) | — | (8.2) |
Restructuring costs | (13.6) | 3.8 | (9.8) |
Back-office digital transformation | (6.3) | 1.9 | (4.4) |
Tax deduction denial (pre-FY2020 claims) | — | (24.5) | (24.5) |
Total | (51.2) | 38.5 | (12.7) |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin statutory (%) | 30.3 | 20.9 | 18.2 | 17.9 | 17.3 |
EBITDA margin underlying (%) | 30.3 | 20.9 | 17.9 | 18.1 | 17.8 |
Pre-tax margin (%) | 22.2 | 11.4 | 8.2 | 7.8 | 7.6 |
Net margin statutory (%) | 15.6 | 8.4 | 5.7 | 5.3 | 5.6 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | 12,552 | 13,015 | 14,826 | 16,054 | 16,781 |
Total liabilities (AUD Mn) | 5,124 | 5,093 | 6,751 | 7,581 | 8,287 |
Net assets incl. minorities (AUD Mn) | 7,428 | 7,922 | 8,075 | 8,473 | 8,493 |
Cash and equivalents (AUD Mn) | 780 | 798 | 645 | 674 | 654 |
Total debt incl. leases, third-party (AUD Mn) | 3,013 | 3,101 | 4,516 | 5,171 | 5,840 |
Net interest-bearing debt ex-leases (AUD Mn) | 812 | 886 | 2,349 | 2,818 | 3,069 |
Gearing ratio (%) | 9.7 | 9.9 | 22.3 | 24.7 | 25.9 |
NTA per share (AUD) | 0.14 | 0.28 | -2.19 | -2.69 | -3.14 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | 2,226 | 1,471 | 1,072 | 1,297 | 1,405 |
Capex, PP&E (AUD Mn) | 287 | 389 | 471 | 336 | 631 |
Free cash flow (AUD Mn) | 1,939 | 1,082 | 601 | 961 | 775 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE after tax (%) | 21.0 | 8.9 | 6.4 | 6.2 | 7.2 |
ROIC after tax (%) | 19.7 | 8.8 | 6.5 | 5.9 | 6.5 |
ROA (%) | 11.6 | 5.3 | 3.4 | 3.2 | 3.6 |
Net debt to equity (%) | 10.9 | 11.2 | 29.1 | 33.3 | 36.1 |
Net debt to EBITDA covenant basis (x) | 0.3 | 0.6 | 1.9 | 2.1 | 2.2 |
Interest cover EBITA basis (x) | 47.3 | 29.4 | 12.0 | 10.1 | 10.0 |
Asset turnover (x) | 0.74 | 0.63 | 0.60 | 0.60 | 0.65 |
Revenue by Region
| Region / segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia & NZ laboratory (AUD Mn) | 1,994 | 2,104 | 2,213 |
Australia radiology (AUD Mn) | 880 | 970 | 1,037 |
Australia other / SCS (AUD Mn) | 446 | 465 | 499 |
Total Australasia (AUD Mn) | 3,320 | 3,539 | 3,749 |
North America – USA laboratory (AUD Mn) | 2,147 | 2,110 | 2,048 |
Europe laboratory (AUD Mn) | 3,475 | 3,975 | 5,055 |
Geographic Revenue
| Region | FY2025 growth (stat.) | FY2026 growth (stat.) | FY2026 share of revenue |
|---|---|---|---|
Australasia (all segments) | 6.6% | 5.9% | 34.5% |
USA | (1.7)% | (2.9)% | 18.9% |
Europe | 14.4% | 27.2% | 46.5% |
Geographic Revenue (FY2026 organic growth (lab)–FY2026 revenue (AUD Mn))
| Country / division | FY2026 revenue (AUD Mn) | % of group | FY2026 organic growth (lab) |
|---|---|---|---|
Germany | 2,729 | 25% | 5% (statutory +43%) |
Australia (pathology) | 2,184 | 20% | 5% |
USA | 2,048 | 19% | 0% (2% underlying) |
Switzerland | 1,173 | 11% | 4% CC (6% in H2) |
UK | 926 | 8% | 17% CC |
Radiology (Australia) | 1,037 | ~10% | 7% |
SCS / Other | 499 | ~5% | 1% organic (5% total) |
Belgium, NZ, Poland, Liechtenstein and other (derived residual) | ~256 | ~2% | Belgium 3% |
Share Price & Returns
| Reference point | Price | Source |
|---|---|---|
Record high (Aug 2021) | ~43.43 intraday | Motley Fool, 27 Aug 2021 |
FY2025 year-end (30 Jun 2025) | 26.79 | InvestSMART/Morningstar |
2025 calendar-year range | 20.50 – 29.24 | InvestSMART |
FY2026 year-end (30 Jun 2026) | 20.81 | InvestSMART |
52-week low (20 May 2026) | 18.26 | InvestSMART |
Pre-result close (19 Aug 2026) | 23.56 | Rivkin |
Post-result close (20 Aug 2026) | 21.38 | Rivkin |
Mid-October 2026 (indicative) | ~21.5–22.0 | Aggregator data; verify live |
Period return (approx., price only) | Return | — |
FY2026 (1 Jul 2025 – 30 Jun 2026) | -22.9% | — |
Calendar 2025 | -16.2% | — |
1-year to mid-Oct 2026 (vs ~A$21.4 on 22 Oct 2025) | ~0% to +3% | — |
3-year TSR to 30 Jun 2026 (company, incl. dividends) | -35.0% | — |
5-year (vs ~A$41–43 in Aug–Oct 2021) | approx. -48% to -50% | — |
Metric | FY2022 | FY2023 |
Enterprise value at 30 June (AUD Mn) | 16,386 | 17,633 |
Rolling 3-year TSR (%) | 32.0 | 27.7 |
Valuation Multiples
| Multiple | Sonic | Basis |
|---|---|---|
P/E (statutory FY2026 EPS 123.1c) | ~17.5x | Computed |
P/E (underlying FY2026 EPS 125.6c) | ~17.1x | Computed |
EV/EBITDA (EV incl. lease liabilities ~A$15.8bn; underlying EBITDA A$1,933m) | ~8.2x | Computed; net debt incl. leases ~A$5.19bn (third-party total debt A$5,840m less cash A$654m) |
EV/Sales | ~1.45x | Computed |
P/B (net assets A$8,493m) | ~1.25x | Computed |
Dividend yield (A$1.08) | ~5.0% (60% franked) | Computed |
P/S vs 5-year average | ~1.0x vs ~1.9x (May 2026) | StockWireX |
Source Details
| Source | View | Date |
|---|---|---|
FNArena consensus target | A$25.41 (7% upside at the time) | Feb 2026 (pre-FY2026 result) |
Jarden | FY2027 EPS forecast 143.2c, DPS 108.3c | Feb 2026 (FY2027 guidance since implies lower growth) |
Morningstar Australia | Shares ~20% below intrinsic value post-result; FY2027 pathology headwinds | Aug 2026 |
Simply Wall St narrative | Fair value ~A$23.36; revenue A$11.9bn and earnings A$749m by 2029 | Aug 2026 |
Consensus vs FY2026 actual | Underlying EPS 125.6c vs analyst forecasts nearer 141c (Rivkin) | Aug 2026 |
Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim dividend (A$ cents) | 40 | 42 | 43 | 44 | 45 |
Final dividend (A$ cents) | 60 | 62 | 63 | 63 | 63 |
Total dividend (A$ cents) | 100 | 104 | 106 | 107 | 108 |
Franking (%) final | 100 | 100 | 0 | 35 | 60 |
Credit Ratings
| Agency | Rating |
|---|---|
Moody's | No public issuer rating identified |
S&P Global | No public issuer rating identified |
Fitch | No public issuer rating identified |
Calendar Year Details
| Calendar year | AUD | USD | EUR | CHF |
|---|---|---|---|---|
| 2026 | 0 | 0 | 200 | 0 |
| 2027 | 450 | 0 | 245 | 0 |
| 2028 | 0 | 0 | 185 | 97 |
| 2029 | 157 | 100 | 304 | 0 |
| 2030 | 0 | 300 | 0 | 0 |
| 2031 | 0 | 0 | 320 | 125 |
| 2032 | 0 | 150 | 85 | 152 |
| 2033 | 0 | 0 | 0 | 100 |
| 2034 | 0 | 0 | 200 | 0 |
| 2035 | 0 | 100 | 0 | 0 |
| 2039 | 0 | 0 | 100 | 0 |
Analyst Conclusions
Management guidance
FY2027 EBITDA of A$1.95–2.03 billion at constant currency, excluding ~A$30m of IT transformation costs and any property gains, assuming no further regulatory changes and only completed acquisitions. Embedded positives: A$25–30m US cost initiatives, LADR and Swiss synergies, US revenue-collection uplift (US$20–25m), radiology greenfield maturation. Embedded negatives: ~CHF20m Swiss fee cut; HWE margins deferred to 2H FY2028; Australian wage pressures. Midpoint implies ~3% EBITDA growth (or ~4–5% adding back excluded IT costs).
Consensus expectations
Pre-result forecasts (e.g., Jarden FY2027 EPS 143.2c) are likely to have been cut after guidance disappointed; Simply Wall St's narrative implies ~4.6% revenue CAGR to 2029. A refreshed post-result consensus should be obtained.
Bull case
-
Self-help is quantified and largely within management control. US cost initiatives (A$25–30m locked in), German divisional consolidation, Swiss lab mergers (Berne, Lucerne) and the deferred US collections uplift together could add well over A$80–100m of EBITDA over FY2027–28 even without top-line acceleration.
-
Valuation embeds pessimism. At ~17x underlying earnings, ~8x EV/EBITDA, ~1.0x sales (vs ~1.9x five-year average) and a ~5% partly franked yield, the stock prices in little recovery in ROIC from 6.5%; modest margin repair would re-rate it.
-
Structural growth pockets and capital recycling. Advanced diagnostics (+12–16%), DTC (>60%) and genetics (+15%) are growing faster than the core, while property recycling (A$445m at 5.6%) and potential Docklands/Macquarie Park SLBs can fund growth or buybacks.
Bear case
-
Returns problem is chronic. ROIC has been 5.9–6.5% for three years; FY2024–26 LTI vested at zero; the market may continue to discount acquisitive growth that earns only around the cost of capital.
-
Regulatory fee pressure is relentless and multi-front. Switzerland (Jul 2026), Germany (EBM; potential reform), Belgium, Australian MBS indexation gaps and wage rulings collectively offset operating leverage.
-
Execution risk under new leadership. US remains a no-growth business against dominant rivals; HWE has slipped; IT transformation (after an A$82.8m software impairment) carries cost and delivery risk; FY2026 underlying EPS missed analyst expectations by a wide margin.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Nov 2026 | 2026 AGM: trading update, guidance reaffirmation, NED re-elections (Mitchell), remuneration vote |
| Nov 2026 | Sustainability Impact Report (emissions, diversity metrics) |
| Ongoing | US operating review outcomes; any portfolio exits or further practice rationalisation |
| Feb 2027 | H1 FY2027 result: margin trajectory, Swiss fee offset, HWE volume transfer |
| H1 CY2027 | Further sale-and-leaseback announcements (Docklands, Macquarie Park); 95 Epping Rd settlement |
| Mid-2027 | Docklands Melbourne hub opening |
| FY2027 | Berne/Lucerne Swiss lab mergers; Bremen reference lab ramp |
| Ongoing | German healthcare reimbursement reform; Australian MBS indexation decisions; Government response on wage-offset funding |
| Ongoing | Capital allocation: payout ratio trend toward 70–80%; potential buyback; bolt-on M&A |
| Ongoing | AUD vs EUR/CHF/USD translation effects |
Analyst verdict
Sonic Healthcare enters FY2027 as a high-quality franchise in a low-return phase. The operating evidence is solid: FY2026 delivered 13% revenue growth, 5% organic growth for the second consecutive year, underlying EBITDA within guidance at A$1.93bn, and a successful first year of LADR, Sonic's most consequential European acquisition. Its market positions — first in five countries, second or third in three more — and its Medical Leadership culture remain genuine moats in a business where referral relationships and pathologist retention determine share.
Yet the financial evidence explains the market's scepticism. Group ROIC of 6.5% is barely above the cost of capital, underlying EBITDA margins have settled below 18% as mix and fee pressures absorb operating leverage, and FY2027 guidance implies only low-single-digit EBITDA growth. Three-year TSR of −35% and zero LTI vesting signal that the post-COVID reset has been longer and deeper than management anticipated. The US remains the problem child, the HWE contract has slipped a year, and FY2026's clean-up items (software impairment, US debtor write-down, tax denial) remind investors that federation-era complexity carries hidden costs.
The new leadership's agenda is the right one: consolidate where scale is already won (Germany into three divisions, Swiss lab mergers), fix or shrink the US, modernise IT, recycle property capital, and make EPS and ROIC the explicit yardsticks. The balance sheet (2.2x leverage, A$1.6bn liquidity) gives time and optionality.
On balance, Sonic screens as a defensive value-recovery story rather than a growth compounder: a ~5% yield and undemanding multiples offer downside support, while re-rating requires visible ROIC improvement — principally US margin repair and German/Swiss synergy delivery — over the next 12–18 months. Investors should treat the FY2027 interim result and the AGM trading update as the key tests of whether Dr Newcombe's "high-value medicine at scale" thesis is translating into returns.
Figures labelled "computed" are derived arithmetically from cited company disclosures. Market prices and multiples are indicative as of mid-October 2026 and should be refreshed against live data.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background / education |
|---|---|---|---|
Dr Jim Newcombe | CEO & Managing Director | CEO since 20 Nov 2025; joined Sonic 2017 | Former CEO, Douglass Hanly Moir Pathology; clinical microbiologist and infectious diseases physician; BMedSci (Hons), MPH (Hons), MBBS, FRACP, FRCPA, GAICD |
Chris Wilks | CFO & Finance Director | Director since Dec 1989; CFO since 1993 | Chartered accounting and investment banking; former partner in a private investment bank; NED of Silex Systems since 1988; BCom, FAICD |
Evangelos Kotsopoulos | Group Chief Operating Officer (new role, from Nov 2025) | Joined 2007 | Former CEO Sonic Healthcare Europe and Germany (Germany, Switzerland, Belgium); prior investment banking career |
Dr Cory A. Roberts | CEO, Sonic Healthcare USA | — | Physician executive |
Dr Mohammed Salama | Chief Medical Officer, Sonic Healthcare USA | — | Pathologist |
Paul Alexander | Deputy CFO (since 1997) & Company Secretary (since 2001) | 29 years | Chartered accountant; BEc, CA, FCSI, GAICD |
Dr Colin Goldschmidt | Former CEO (1993–Nov 2025); part-time unpaid Advisor to the Board; Chair, Sonic Healthcare Foundation | 32 years as CEO | Pathologist |
“—” = not publicly disclosed.
Directors' Remuneration
| Executive | Fixed remuneration | Target STI | Actual STI awarded | % of target | LTI vesting (FY24–26 tranche) |
|---|---|---|---|---|---|
Dr J Newcombe (from 20 Nov 2025) | A$1,750,000 p.a. (pro-rated ≈A$1.07m) | A$1,069,178 | A$948,073 | 88.7% | — |
Dr C Goldschmidt (to 19 Nov 2025) | Pro-rated (≈A$0.93m implied) | A$856,423 | A$759,416 | 88.7% | 0% |
C Wilks | A$1,200,000 (unchanged since 2023) | A$1,563,206 (incl. A$300k integration STI) | A$1,420,123 | 90.8% | 0% |
Board of Directors
| Director | Role | Appointed | Independence | Committees | Background |
|---|---|---|---|---|---|
Prof Mark Compton AM | Chairman | Oct 2014 (Chair Nov 2015) | Independent NED | Audit; Remuneration & Nomination | Former CEO Royal Flying Doctor Service, St Luke's Care; NED HCF |
Dr Jim Newcombe | MD & CEO | Nov 2025 | Executive | Risk Management | Pathologist (microbiology) |
Chris Wilks | Finance Director | Dec 1989 | Executive | — | CFO since 1993 |
Prof Suzanne Crowe AO | NED | Apr 2020 | Independent | Chair Risk Management; Rem & Nom | Infectious diseases physician-scientist; NED Avita Medical |
Emer. Prof Christine Bennett AO | NED | Sep 2022 | Independent | Risk Management | Paediatrician; NED Regis Healthcare, Australian Digital Health Agency |
Kate Spargo | NED | Jul 2010 | Independent | Chair Rem & Nom (stepping down after 2026 AGM); Audit | Lawyer; NED Bapcor, CIMIC; retiring from Board by 2027 |
Neville Mitchell | NED | Sep 2017 | Independent | Chair Audit; Risk Management | Former CFO Cochlear; Chair Fisher & Paykel Healthcare; NED Sigma Healthcare; to retire by 2029 if re-elected 2026 |
Dr Katharine Giles | NED | Sep 2022 | Independent | — | MD/CEO OncoRes Medical; Venture Partner Brandon Capital |
Nicola Wakefield Evans AM | NED | Feb 2025 | Independent | Rem & Nom (incoming Chair) | Former KWM partner; Future Fund Guardian; NED Qube, CEFC; Chair MetLife Australia |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
25 Sep 2025 | CEO succession announced; COO role created | Shares fell on announcement; insider succession |
20 Nov 2025 | Goldschmidt retires; Newcombe CEO; Kotsopoulos COO | Goldschmidt retains equity, unpaid advisor; mentors new DHM CEO |
FY2026 | "Several key appointments" to strengthen executive team (names not disclosed in AR) | Global Leaders Summit set strategic priorities to 2030 |
Post-2026 AGM | Spargo hands Rem & Nom chair to Wakefield Evans | Board renewal |
Major Shareholders
| Holder | Shares / stake | Date | Source |
|---|---|---|---|
State Street Corporation & subsidiaries | 36,384,812 (7.36%), down from 8.78% | 1 Sep 2026 | Substantial holder notice, 3 Sep 2026 |
Citigroup Global Markets Australia & related | 26,383,442 (5.34%) — largely agent-lending positions | 19 Aug 2026 | Notice, 21 Aug 2026 |
The Vanguard Group | — | 12 Aug 2026 | Notice, 18 Aug 2026 |
UBS Group AG | Ceased to be substantial holder | 1 Sep 2026 | Notice, 3 Sep 2026 |
LADR sellers (now Sonic Germany leadership) | 13.8 million shares issued (~2.8%) | 1 Jul 2025 | AR2026 |
Competitive Landscape
Competitors by Segment
| Segment / market | Competitor | Ownership | Relative positioning vs Sonic |
|---|---|---|---|
Australian pathology | Healius (Laverty, Dorevitch, QML, Western Diagnostic) | ASX: HLS | #2; financially weakened, sold Lumus Imaging; shares at record lows (2025) |
Australian pathology | Australian Clinical Labs (ACL) | ASX: ACL | #3; attempted Healius takeover 2023 |
Australian imaging | I-MED Radiology Network | Private equity | #1 imaging (Sonic #2) |
Australian imaging | Integral Diagnostics (merged with Capitol Health) | ASX: IDX | Scale challenger |
Australian imaging | Lumus Imaging | Private (ex-Healius) | Competitor |
US laboratory | Labcorp | NYSE: LH | #1 US lab; ~US$13.0bn revenue (CY2024) |
US laboratory | Quest Diagnostics | NYSE: DGX | #2 US lab; ~US$9.87bn revenue (CY2024) |
US anatomical pathology | PathGroup, regional AP groups, hospital labs | Private | Fragmented |
Germany | Limbach Gruppe; Amedes; SYNLAB Germany | Private / PE (Cinven for SYNLAB) | Sonic #1 private |
Europe (multi-country) | SYNLAB | Cinven (delisted 2024) | Major pan-European rival |
Europe (multi-country) | Unilabs | Private (A.P. Møller Holding) | Switzerland, Europe |
Europe | Cerba HealthCare | PE-owned | France/Belgium/Europe |
Europe (clinical + esoteric) | Eurofins Scientific | Euronext: ERF | Diversified testing; ~€6.95bn revenue (CY2024) |
UK | Synnovis (Synlab/NHS JV), NHS in-house networks | JV / public | Competes for NHS outsourcing |
Belgium | Cerba, Synlab, hospital labs | Various | Sonic #2 |
Peer Comparison FY2026
| Metric | Sonic Healthcare | Labcorp | Quest Diagnostics | Eurofins Scientific |
|---|---|---|---|---|
Latest annual revenue | A$10.87bn FY2026 (~US$7.4bn at FY2026 avg 0.6787) | ~US$13.0bn (CY2024) | ~US$9.87bn (CY2024) | ~€6.95bn (CY2024) |
Revenue growth | 12.7% (FY2026) | ~7% (CY2024) | ~6.7% (CY2024) | ~6.6% (CY2024) |
EBITDA margin | 17.8% underlying (FY2026) | — | — | — |
Geographic mix | 46% Europe, 35% Australasia, 19% USA | Predominantly US | Predominantly US | Predominantly Europe |
